Samrat Pharmachem Key Ratios
BSE: 530125
₹235.00
As on 01-Sep-2026 12:22IST
Market cap
₹73 Cr
Revenue (TTM)
₹294 Cr
P/E Ratio
--
P/B Ratio
1.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 11.13 | 5.43 | 4.68 | 1.42 | 8.99 |
| EBIT | 149.69 | 1,680.00 | -129.57 | -157.33 | -176.47 |
| Net Profit | 142.98 | 482.53 | -145.87 | -165.47 | -183.31 |
| EPS | 142.98 | 482.54 | -145.87 | -165.47 | -183.36 |
| Book Value | -- | -- | 10.47 | 15.32 | 24.19 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-25 | Mar-24 |
| EBIT-Margin
| 3.83 | 5.34 | -0.72 | 3.35 | 0.64 |
| Net Margin
| 2.86 | 3.86 | -0.75 | 2.48 | 0.76 |
| Return on equity
| 14.67 | 21.75 | -3.18 | 10.40 | 3.38 |
| Return on Capital
| 17.55 | 25.78 | -- | 13.61 | 4.13 |
| Return on Assets
| 8.06 | 11.52 | -1.80 | 5.85 | 1.81 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.14 | 0.13 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
--
|
13.61
|
4.13
|
34.91
|
52.33
|
|
Peer Median
|
--
|
10.67
|
24.98
|
20.19
|
--
|
ROE
-3.18
Lower than Peers by 13.58
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
-3.18
|
10.40
|
3.38
|
30.25
|
44.95
|
|
Peer Median
|
10.40
|
7.59
|
20.21
|
19.34
|
--
|
ROA
-1.80
Lower than Peers by 8.22
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
-1.80
|
5.85
|
1.81
|
16.53
|
24.20
|
|
Peer Median
|
6.43
|
5.44
|
12.91
|
11.01
|
--
|
EBIT Margin
-0.72
Lower than Peers by 11.92
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
-0.72
|
3.35
|
0.64
|
7.50
|
10.66
|
|
Peer Median
|
11.21
|
11.66
|
11.54
|
15.47
|
--
|
Net Margin
-0.75
Lower than Peers by 8.61
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
-0.75
|
2.48
|
0.76
|
5.35
|
7.73
|
|
Peer Median
|
7.86
|
7.57
|
9.71
|
10.37
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
--
|
2.72
|
1.00
|
5.56
|
8.02
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
4.68
Lower than Peers by 1.11
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
4.68
|
1.52
|
-9.36
|
40.09
|
23.87
|
|
Peer Median
|
5.79
|
9.11
|
-10.85
|
39.46
|
--
|
EBIT Growth
-129.57
Lower than Peers by 125.79
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
-129.57
|
431.19
|
-92.25
|
-1.51
|
189.18
|
|
Peer Median
|
-3.79
|
6.88
|
-32.98
|
80.25
|
--
|
Net Profit Growth
-145.87
Lower than Peers by 146.96
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
-145.87
|
228.87
|
-87.00
|
-3.23
|
222.22
|
|
Peer Median
|
1.09
|
16.56
|
-31.20
|
77.33
|
--
|
EPS Growth
-145.87
Lower than Peers by 145.95
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
-145.87
|
228.87
|
-87.00
|
-3.23
|
222.22
|
|
Peer Median
|
0.08
|
20.92
|
--
|
80.00
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
--
|
10.47
|
2.94
|
34.86
|
57.98
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
--
|
0.14
|
0.13
|
0.30
|
0.16
|
|
Peer Median
|
0.05
|
0.07
|
0.15
|
0.25
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
--
|
0.14
|
0.13
|
0.30
|
0.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.86
Higher than Peers by 0.16
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
1.86
|
2.08
|
1.82
|
1.86
|
1.91
|
|
Peer Median
|
1.70
|
1.68
|
1.57
|
1.55
|
--
|
Quick Ratio
1.08
Higher than Peers by 0.08
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
1.08
|
1.32
|
1.45
|
1.25
|
1.58
|
|
Peer Median
|
0.99
|
1.31
|
1.19
|
0.97
|
--
|
Interest Coverage
-1.54
Lower than Peers by 11.67
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
-1.54
|
15.67
|
4.67
|
19.29
|
35.99
|
|
Peer Median
|
10.13
|
7.47
|
19.21
|
17.50
|
--
|
Operating Efficiency
Debtors to sales
17.37
Higher than Peers by 4.09
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
17.37
|
19.78
|
24.60
|
16.63
|
19.65
|
|
Peer Median
|
13.28
|
14.65
|
12.34
|
12.61
|
--
|
Asset Turnover
2.39
Higher than Peers by 1.60
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
2.39
|
2.35
|
2.36
|
3.09
|
3.12
|
|
Peer Median
|
0.79
|
0.86
|
0.92
|
1.17
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
--
|
80.32
|
78.39
|
55.96
|
63.02
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
--
|
37.46
|
34.48
|
26.40
|
19.60
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
--
|
59.00
|
53.71
|
36.30
|
39.45
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
--
|
58.79
|
59.17
|
46.06
|
43.17
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
-33.66
Lower than Peers by 62.64
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
-33.66
|
13.59
|
47.64
|
6.89
|
8.72
|
|
Peer Median
|
28.98
|
40.01
|
28.36
|
14.07
|
--
|
Price / Book Value
1.06
Lower than Peers by 1.18
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
1.06
|
1.35
|
1.59
|
1.82
|
3.20
|
|
Peer Median
|
2.24
|
1.93
|
2.13
|
2.38
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
--
|
0.32
|
0.30
|
0.27
|
0.21
|
|
Peer Median
|
0.42
|
0.27
|
0.45
|
0.44
|
--
|
EV/EBITDA
-333.73
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
-333.73
|
9.49
|
26.40
|
4.98
|
5.73
|
|
Peer Median
|
--
|
22.60
|
12.16
|
12.87
|
--
|
Market Cap
73
Lower than Peers by 1,559
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Samrat Pharmachem
|
73
|
97
|
103
|
115
|
150
|
|
Peer Median
|
1,632
|
1,454
|
1,457
|
1,879
|
--
|